Ambarella Introduces CV5 High Performance AI Vision Processor for Single 8K and Multi-Imager AI Cameras
11.1.2021 13:00:00 EET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today unveiled CV5, an artificial intelligence (AI) vision processor capable of recording 8K video or four 4K video streams. The new system on chip (SoC) will enable the development of intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. It combines Ambarella’s powerful CVflow AI engine with dual Arm® A76 CPUs to provide the performance necessary for a wide range of AI-based algorithms. Its advanced image signal processor (ISP) can simultaneously process images for both human viewing and machine processing. Fabricated in advanced 5 nm process technology, CV5 consumes under 2 watts of power while encoding full 8K video at 30 frames per second.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005235/en/
Ambarella today unveiled the CV5 AI vision CVflow® 5 nm processor for single 8K and multi-imager AI cameras, setting a new standard for power efficiency with 8K video recording in under 2 watts. The SoC targets intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. (Photo: Business Wire)
“With the introduction of CV5, Ambarella is defining the next generation of automotive, consumer, and robotic cameras,” said Fermi Wang, CEO of Ambarella. “By combining 8K single-channel and 4K multi-channel recording with the high performance of our CVflow AI engine, we are enabling cameras with the highest-quality imaging and innovative new AI features.”
In automotive video telematics applications, CV5 provides the performance necessary to encode multiple video streams from front ADAS, driver monitoring, cabin monitoring, and side-view cameras. Its CVflow AI engine can simultaneously run advanced driver assistance systems (ADAS) algorithms such as lane departure, and forward collision warning as well as driver monitoring algorithms such as drowsy driver detection. The combination of high-resolution video capture with advanced AI processing enables ADAS cameras to recognize images over long distances and with high accuracy.
The exceptionally low power consumption of the CV5 SoC also makes it an ideal solution for the next generation of high resolution and high frame-rate action, 360°, and virtual reality (VR) cameras, offering 8K recording and playback in very small form factor designs.
In robotic and drone applications, CV5’s CVflow AI engine can accelerate simultaneous localization and mapping (SLAM), path planning, and obstacle detection, and avoidance algorithms for navigation and autonomous operation. For drone-based aerial videography and cinematography, CV5 can simultaneously perform flight control and navigation functions while recording up to 8K resolution video recording at 60 frames per second.
The CV5 SoC shares common SDK and computer vision (CV) tools with Ambarella’s other CVflow SoC families, simplifying development of cameras with multiple price and performance options. A complete set of CV tools helps customers port their own neural networks onto CV5, including a compiler, debugger, and support for industry-standard machine learning frameworks, such as PyTorch™, ONNX™, Caffe™, and TensorFlow™, as well as extensive guidelines for convolutional neural network (CNN) performance optimization.
CV5 SoC key features:
- CVflow architecture with DNN support
- Dual-core Arm® Cortex®-A76 up to 1.6 GHz with NEON™ DSP extensions and FPU
- High-speed SLVS-EC, MIPI-CSI (C/D PHY) interfaces, connecting up to 14 cameras
- Multi-channel ISP with up to 8KP60 throughput
- Native support for RGGB, RCCB, RCCC, RGB-IR, and monochrome sensor formats
- Multi-exposure high dynamic range (HDR) processing
- Real-time, hardware-accelerated fisheye dewarping and lens distortion correction (LDC)
- AVC and HEVC encoding with up to 8KP60 throughput and multiple stream support
- Rich set of interfaces includes 4-lane PCIe, CAN FD, Gigabit Ethernet, USB 3.1 host and device, three SD card controllers, MIPI DSI/CSI-2 and HDMI video outputs
- LPDDR4x / LPDDR5 / LPDDR5x support, 64-bit data bus and up to 32 GB capacity
- Advanced security features, including secure boot with TrustZone® and secure memory, TRNG, OTP, DRAM scrambling and virtualization
- 5 nm process technology
- 16x16 FBGA package with 0.5 mm ball pitch
About Ambarella, Inc.
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. © 2021 Ambarella, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005235/en/
Contact information
Ambarella Contact: www.ambarella.com/about/contact/inquiries
Media Contact: Molly McCarthy, Valley Public Relations, mmccarthy@ambarella.com
Investor Relations Contact: Louis Gerhardy, Ambarella, lgerhardy@ambarella.com, (408) 636-2310
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
